Once-daily venlafaxine extended release (XR) compared with fluoxetine in outpatients with depression and anxiety

Journal of Clinical Psychiatry

Volumn 60, Issue 1, 1999, Pages 22-28

  Silverstone, Peter H ^a,c   Ravindran, Arun ^b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

^c UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORAL HYDRATE; CISAPRIDE; FLUOXETINE; PAROXETINE; PLACEBO; VENLAFAXINE;

ADULT; ANXIETY NEUROSIS; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; ORAL DRUG ADMINISTRATION; OUTPATIENT; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SUSTAINED RELEASE PREPARATION; VERTIGO; VOMITING;

EID: 0032910491     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v60n0105     Document Type: Article

References (33)

1. Fawcett J, Kravitz HM. Anxiety syndromes and their relationship to depressive illness. J Clin Psychiatry 1983;44(8, pt 2):8-11
2. Clayton PJ, Grove WM, Coryell W, et al. Follow-up and family study of anxious depression. Am J Psychiatry 1991;148:1512-1517
3. Fawcett J, Scheftner WA, Fogg L, et al. Time-related predictors of suicide in major affective disorder. Am J Psychiatry 1990;147:1189-1194
4. Goldberg D, Bridges K, Duncan-Junes P, et al. Detecting anxiety and depression in general medical settings. BMJ 1988;297:898-899
5. Ormel J, Koeter MWJ, van den Brink W, et al. Recognition, management, and course of anxiety and depression in general practice. Arch Gen Psychiatry 1991;48:700-706
6. Stein MB, Kirk P, Prabhu V, et al. Mixed anxiety-depression in a primary care clinic. J Affect Disord 1995;34:79-84
7. Lecruhier Y, Bourin M, Moon CAL, et al. Efficacy of venlafaxine in depressive illness in general practice. Acta Psychiatr Scand 1997;95:458-463
8. Rudolph RL, Entsuah R, Chitra R. A meta-analysis of the effects of venlafaxine on anxiety associated with depression. J Clin Psychopharmacol 1998;18:136-144
9. Troy SM, Parker VD, Fruncillo RJ, et al. The pharmacokinetics of venlafaxine when given in a twice-daily regimen. J Clin Pharmacol 1995;35:404-409
10. Troy SM, DiLea C, Martin PT, et al. Pharmacokinetics of once-daily venlafaxine extended release (XR) in healthy volunteers. Cur Ther Res 1997;58:504-514
11. Troy SM, DiLea C, Martin PT, et al. Bioavailability of once-daily venlafaxine extended release (XR) compared with the immediate release formulation in healthy adult volunteers. Cur Ther Res 1997;58:492-503
12. Cunningham LA, for the Venlafaxine XR 208 Study Group. Once-daily venlafaxine extended release (XR) and venlafaxine immediate release in outpatients with major depression. Ann Clin Psychiatry 1997;9:157-164
13. Thase ME, for the Venlafaxine XR 209 Study Group. Efficacy and tolerability of once-daily venlafaxine extended release (XR) in outpatients with major depression. J Clin Psychiatry 1997;58:393-398
14. Feighner JP, Entsuah AR, McPherson MK. Efficacy of once-daily venlafaxine extended release (XR) for symptoms of anxiety in depressed outpatients. J Affect Disord 1998;47:55-62
15. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Washington, DC: American Psychiatric Association; 1994
16. Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 1967;6:278-296
17. Lipman R, Covi L. Outpatient treatment of neurotic depression: medication and group psychotherapy. In: Spitzer RL, Klein DL, eds. Evaluation of the Psychological Therapies, Baltimore, Md: Johns Hopkins University Press: 1976
18. Hamilton M. The assessment of anxiety slates by rating. Br J Med Psychol 1959;32:50-55
19. Zigmond AS, Snaith RP. The Hospital Anxiety and Depression Scale. Acta Psychiatr Scand 1983;67:361-370
20. Guy W. ECDEU Assessment Manual for Psychopharmacology. US Dept Health, Education, and Welfare publication (ADM) 76-338. Rockville, Md: National Institute of Mental Health; 1976:218-222
21. Clerc GE, Ruimy P, Verdeau-Pailles J. A double-blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholia. Im Clin Psychopharmacol 1994;9:138-143
22. Salinas E, for the Venlafaxine XR Study Group. Dose-response effects of once-daily extended release (XR) venlafaxine in outpatients with major depression [abstract]. Biol Psychiatry 1997;42:2445
23. Dierick M, Ravizza L, Realini R, et al. A double-blind comparison of venlafaxine and fluoxetine for treatment of major depression in outpatients. Prog Neuropsychopharmacol Biol Psychiatry 1996;20:57-71
24. Thase ME, Rush AJ, Kasper S, et al. Tricyclics and newer antidepressant medications: treatment options for treatment-resistant depressions. Depression 1995;2:152-168
25. Klerman GL, Weissman MM, Frank E, et al. Evaluating drug treatments of depressive disorders. In: Prien RF, Robinson DS, eds. Clinical Evaluation of Psychotropic Drugs: Principles and Guidelines. New York, NY: Raven Press; 1994:281-325
26. Null D. Management of patients with depression associated with anxiety symptoms. J Clin Psychiatry 1997;58(suppl 8): 11-16
27. Amsterdam JD, Hornig-Rohan M, Matslin G. Efficacy of alprazolam in reducing fluoxetine-induced jitteriness in patients with major depression. J Clin Psychiatry 1994;55:394-400
28. Ereshefsky L. Drug-drug interactions involving antidepressants: focus on venlafaxine. J Clin Psychopharmacol 1996:16(suppl 2):37S-50S
29. Danjou P, Hackett D. Safety and tolerance profile of venlafaxine. Int Clin Psychopharmacol 1995;10(suppl 2): 15-20
30. Poirier M-F. Venlafaxine versus paroxetine in the treatment of resistant depression [abstract]. Biol Psychiatry 1997;42:243S
31. Roose SP, Glassman AH, Attia E, et al. Comparative efficacy of selective serotonin reuptake inhibitors and tricyclics in the treatment of melancholia. Am J Psychiatry 1994;151:1735-1739
32. Danish University Antidepressant Group. Citalopram: clinical effect profile in comparison with clomipramine: a controlled multicenter study. Psychopharmacology (Berl) 1986;90:131-138
33. Danish University Antidepressant Group. Paroxetine: a selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter study. J Affect Disord 1990;18:289-299